Investors

2023

OptiBiotix Health Plc (AIM:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces it has completed testing and primary data analysis on its capsular food supplement to reduce cholesterol, and commenced pilot manufacturing studies.

The aim of the human study was to establish safety and compliance, and to assess the extent of the lowering potential of its product in this group of volunteers. Sample testing and primary data analysis has now been completed and in accordance with the option agreement announced in June 2015, the results are being shared with a multinational consumer goods company.

The terms of the option agreement are bound by confidentiality and no further details on the agreement or human studies can be disclosed at this time.

The company also announces it has commenced pilot manufacturing studies to define the scale up requirements to take the strain from laboratory to pilot scale manufacture. These studies are important in determining the best microbial growth conditions to optimise production yields and volumes.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the completion of clinical studies on our capsular food supplement and the sharing of data with our global partner. The product is now undergoing pilot scale manufacturing studies to maximise production yields and volumes. This will allow us to progress both the supply and longer term commercial aspects in parallel."

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

2022

OptiBiotix Health Plc (AIM:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces it has completed testing and primary data analysis on its capsular food supplement to reduce cholesterol, and commenced pilot manufacturing studies.

The aim of the human study was to establish safety and compliance, and to assess the extent of the lowering potential of its product in this group of volunteers. Sample testing and primary data analysis has now been completed and in accordance with the option agreement announced in June 2015, the results are being shared with a multinational consumer goods company.

The terms of the option agreement are bound by confidentiality and no further details on the agreement or human studies can be disclosed at this time.

The company also announces it has commenced pilot manufacturing studies to define the scale up requirements to take the strain from laboratory to pilot scale manufacture. These studies are important in determining the best microbial growth conditions to optimise production yields and volumes.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the completion of clinical studies on our capsular food supplement and the sharing of data with our global partner. The product is now undergoing pilot scale manufacturing studies to maximise production yields and volumes. This will allow us to progress both the supply and longer term commercial aspects in parallel."

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

2021

OptiBiotix Health Plc (AIM:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces it has completed testing and primary data analysis on its capsular food supplement to reduce cholesterol, and commenced pilot manufacturing studies.

The aim of the human study was to establish safety and compliance, and to assess the extent of the lowering potential of its product in this group of volunteers. Sample testing and primary data analysis has now been completed and in accordance with the option agreement announced in June 2015, the results are being shared with a multinational consumer goods company.

The terms of the option agreement are bound by confidentiality and no further details on the agreement or human studies can be disclosed at this time.

The company also announces it has commenced pilot manufacturing studies to define the scale up requirements to take the strain from laboratory to pilot scale manufacture. These studies are important in determining the best microbial growth conditions to optimise production yields and volumes.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the completion of clinical studies on our capsular food supplement and the sharing of data with our global partner. The product is now undergoing pilot scale manufacturing studies to maximise production yields and volumes. This will allow us to progress both the supply and longer term commercial aspects in parallel."

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

2020

OptiBiotix Health Plc (AIM:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces it has completed testing and primary data analysis on its capsular food supplement to reduce cholesterol, and commenced pilot manufacturing studies.

The aim of the human study was to establish safety and compliance, and to assess the extent of the lowering potential of its product in this group of volunteers. Sample testing and primary data analysis has now been completed and in accordance with the option agreement announced in June 2015, the results are being shared with a multinational consumer goods company.

The terms of the option agreement are bound by confidentiality and no further details on the agreement or human studies can be disclosed at this time.

The company also announces it has commenced pilot manufacturing studies to define the scale up requirements to take the strain from laboratory to pilot scale manufacture. These studies are important in determining the best microbial growth conditions to optimise production yields and volumes.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the completion of clinical studies on our capsular food supplement and the sharing of data with our global partner. The product is now undergoing pilot scale manufacturing studies to maximise production yields and volumes. This will allow us to progress both the supply and longer term commercial aspects in parallel."

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

2019

OptiBiotix Health Plc (AIM:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces it has completed testing and primary data analysis on its capsular food supplement to reduce cholesterol, and commenced pilot manufacturing studies.

The aim of the human study was to establish safety and compliance, and to assess the extent of the lowering potential of its product in this group of volunteers. Sample testing and primary data analysis has now been completed and in accordance with the option agreement announced in June 2015, the results are being shared with a multinational consumer goods company.

The terms of the option agreement are bound by confidentiality and no further details on the agreement or human studies can be disclosed at this time.

The company also announces it has commenced pilot manufacturing studies to define the scale up requirements to take the strain from laboratory to pilot scale manufacture. These studies are important in determining the best microbial growth conditions to optimise production yields and volumes.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the completion of clinical studies on our capsular food supplement and the sharing of data with our global partner. The product is now undergoing pilot scale manufacturing studies to maximise production yields and volumes. This will allow us to progress both the supply and longer term commercial aspects in parallel."

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

2018

OptiBiotix Health Plc (AIM:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces it has completed testing and primary data analysis on its capsular food supplement to reduce cholesterol, and commenced pilot manufacturing studies.

The aim of the human study was to establish safety and compliance, and to assess the extent of the lowering potential of its product in this group of volunteers. Sample testing and primary data analysis has now been completed and in accordance with the option agreement announced in June 2015, the results are being shared with a multinational consumer goods company.

The terms of the option agreement are bound by confidentiality and no further details on the agreement or human studies can be disclosed at this time.

The company also announces it has commenced pilot manufacturing studies to define the scale up requirements to take the strain from laboratory to pilot scale manufacture. These studies are important in determining the best microbial growth conditions to optimise production yields and volumes.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the completion of clinical studies on our capsular food supplement and the sharing of data with our global partner. The product is now undergoing pilot scale manufacturing studies to maximise production yields and volumes. This will allow us to progress both the supply and longer term commercial aspects in parallel."

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.